Biomay – your One-stop Manufacturer

Biomay Offers Lipid-Nanoparticle Formulation Services for RNA Pharmaceuticals

(March 4th, 2025) Biomay now offers GMP services for lipid-based nanoparticles (LNPs). With this, the company has completed its end-to-end platform for manufacturing of GMP-grade mRNA drugs from scratch. A comprehensive list of LNP-specific and GMP-conform analytical assays support that service offering …

Biomay Distributes Lentivirus Starting Plasmids Off-the Shelf

(March 3rd, 2025) Lentivirus starting plasmids are Biomay’s most recent off-the-shelf offering, as the company announced. The set of pre-manufactured lentiviral plasmids are designated for the manufacture of recombinant lentiviral gene transfer vectors.
The offered DNA plasmids are immediately available in “RUO” (research use only) quality, whereas GMP-grade lentiviral plasmids will be offered in a few months …

Biomay Offers AAV Starting Plasmids in GMP and Research Quality – Off-the Shelf

(October 17th, 2024) Biomay now offers ready-made starting plasmids for the manufacture of recombinant adeno-associated virus (rAAV) vectors.

The offered DNA plasmids are immediately available in the quality grades “RUO” and “GMP”. The new catalog products are available off-the-shelf and distributed via Biomay‘s webshop …

Areterna and Biomay Announce Strategic Partnership to Jointly Serve mRNA CDMO Customers in Europe and North America

(September 18th, 2024) Areterna LLC, a company with a mission to democratize mRNA products by supplying low-cost GMP raw materials, announced it has entered a strategic partnership with Biomay, a seasoned CDMO that offers GMP manufacturing of mRNA, plasmid DNA and recombinant proteins …

Biomay Announces its Successful Support of Approval of First CRISPR/Cas9-based Therapy

(January 25th, 2024) Biomay, a biotech contract development and manufacturing organization based in Vienna, Austria,
announces successful completion of an FDA inspection qualifying Biomay as a cGMP manufacturer
and supplier of recombinant nuclease Cas9 for use in gene editing therapies.

Biomay Announces Expansion of its GMP-Facilities to Offer mRNA Manufacturing and Aseptic Filling Services

(October 2023) Biomay, a Vienna based biotech manufacturer, announced a facility extension and is now able to expand its GMP-facilities, to offer mRNA manufacturing and aseptic filling services.

Biomay Cooperates with BioNTech to Supply DNA Template for COVID-19 mRNA Vaccine

(May 17th, 2021) Biomay, a Vienna based biotech manufacturer, today announced their partnership with BioNTech SE to support the supply chain for manufacturing of the Pfizer-BioNTech COVID-19 mRNA vaccine.

Construction Project of Biomay’s Manufacturing Facility Fully on Schedule

(May 12th, 2021) Construction work on Biomay’s new headquarters and biotech manufacturing facility in Aspern Seestadt, Vienna, is progressing on schedule. Seven months after the groundbreaking ceremony …

Biomay to Construct a New Biotech Manufacturing Facility in Vienna

(December 15th, 2020) Biomay, a Vienna-based biotech company, is constructing a new production facility which will increase its manufacturing capacities tenfold and its headcount almost twofold. The new headquarters in Aspern Seestadt, Vienna …

BIA Separations and Biomay collaborate on production and purification of large DNA plasmids

(May 16th, 2018) BIA Separations, a leading biochromatography development and manufacturing company, and Biomay, a contact manufacturer of cGMP biopharmaceuticals, today announced a collaboration on the high-yield production of large DNA plasmids.

Biomay and RBPS-Technologies Sign Agreement for GMP Minicircle DNA

(July 27th, 2009) Biomay and RBPS-Technologies announce their manufacturing cooperation for production of GMP-grade minicircle DNA. The companies are now offering a contract manufacturing service to third parties to supply minicircles in both clinical quality for use in clinical trials and research quality.